BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9704868)

  • 1. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
    Hollander E; Kwon J; Weiller F; Cohen L; Stein DJ; DeCaria C; Liebowitz M; Simeon D
    Psychiatry Res; 1998 Jul; 79(3):213-7. PubMed ID: 9704868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine.
    Simeon D; Hollander E; Stein DJ; DeCaria C; Cohen LJ; Saoud JB; Islam N; Hwang M
    Psychiatry Res; 1995 Sep; 58(2):161-4. PubMed ID: 8570768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
    Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
    Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
    Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
    Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
    Broocks A; Pigott TA; Hill JL; Canter S; Grady TA; L'Heureux F; Murphy DL
    Psychiatry Res; 1998 Jun; 79(1):11-20. PubMed ID: 9676822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
    Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
    Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J
    Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Validation of a scale for responsibility (Salkovskis Responsibility Scale)].
    Bouvard M; Robbe-Grillet P; Milliery M; Pham S; Amireche S; Fanget F; Guerin J; Cottraux J
    Encephale; 2001; 27(3):229-37. PubMed ID: 11488253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder.
    Bastani B; Nash JF; Meltzer HY
    Arch Gen Psychiatry; 1990 Sep; 47(9):833-9. PubMed ID: 2203327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic variants of the serotonin(2C) receptor and neuroendocrinological responses to the serotonin(2C) receptor agonist m-chlorophenylpiperazine in healthy male volunteers.
    Kühn KU; Quednow BB; Bagli M; Meyer K; Feuchtl A; Westheide J; Frahnert C; Maier W; Rao ML
    Pharmacopsychiatry; 2002 Nov; 35(6):226-30. PubMed ID: 12518270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD.
    Hollander E; Cohen LJ; DeCaria C; Saoud JB; Stein DJ; Cooper TB; Islam NN; Liebowitz MR; Klein DF
    Biol Psychiatry; 1993 Sep; 34(6):407-13. PubMed ID: 8218609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
    McCann UD; Eligulashvili V; Mertl M; Murphy DL; Ricaurte GA
    Psychopharmacology (Berl); 1999 Nov; 147(1):56-65. PubMed ID: 10591869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder.
    McBride PA; DeMeo MD; Sweeney JA; Halper J; Mann JJ; Shear MK
    Biol Psychiatry; 1992 Jan; 31(1):19-34. PubMed ID: 1311964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo.
    Pallanti S; Bernardi S; Quercioli L; DeCaria C; Hollander E
    CNS Spectr; 2006 Dec; 11(12):956-64. PubMed ID: 17146409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
    Khanna S; John JP; Reddy LP
    Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects.
    Broocks A; Meyer T; Gleiter CH; Hillmer-Vogel U; George A; Bartmann U; Bandelow B
    Psychopharmacology (Berl); 2001 May; 155(3):234-41. PubMed ID: 11432685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects.
    Cohen LJ; Hollander E; DeCaria CM; Stein DJ; Simeon D; Liebowitz MR; Aronowitz BR
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):82-5. PubMed ID: 8845706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
    Goodman WK; McDougle CJ; Price LH; Barr LC; Hills OF; Caplik JF; Charney DS; Heninger GR
    Biol Psychiatry; 1995 Aug; 38(3):138-49. PubMed ID: 7578657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
    de Leeuw AS; Westenberg HG
    J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures.
    Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B
    Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.